#Oxford #UK #digital health #Caristo Diagnostics #Michel Lussier

Michel Lussier Joins the Board of Caristo Diagnostics

In a significant move for the field of digital health, Caristo Diagnostics has announced that Michel Lussier has joined its board of directors, effective immediately. Caristo, recognized globally for its pioneering work in cardiovascular disease diagnostics and risk assessment, continues to strengthen its leadership as it strives to enhance healthcare outcomes through advanced technologies.

A Leader in MedTech and Digital Health

Michel Lussier is a recognized figure in the MedTech, Biotech, and Digital Health sectors, bringing a wealth of experience in business and operational strategies to Caristo. With a distinguished career that includes executive roles in major companies, he is expected to provide invaluable insights as the organization continues to focus on its mission of improving cardiovascular health diagnostics.

Oran Muduroglu, chairman of Caristo Diagnostics, expressed confidence in Lussier’s appointment, highlighting his “deep technical expertise” and “executive experience” which are bound to be tremendous assets for the board. Lussier’s background includes a successful track record as a former CEO, where he demonstrated skills in shareholder value creation and the management of company growth.

Experience that Speaks Volumes

Before his current role at Caristo, Lussier devoted 15 years to leading Medtronic’s cardiac device business across Europe, Africa, the Middle East, and India. His extensive experience also includes senior leadership and board positions at various private and publicly listed companies, such as Celyad, Volcano Corp., InControl, and Novoste. As the chairman of Liva Healthcare, Lussier continues to influence advancements in digital therapeutics, and at Gabi SmartCare, he contributes to the evolution of wearable medical technology.

A Vision for Innovation

In his statement regarding the new role, Lussier referenced Caristo’s breakthrough technology for visualizing cardiac inflammation, emphasizing the importance of innovation in healthcare. He expressed excitement about working alongside the Caristo team to expand its market reach, ultimately aiming to enhance the quality of life for millions worldwide with its innovative diagnostic solutions.

Commitment to Education and Mentorship

Apart from his corporate roles, Michel Lussier contributes to the academic community as a professor. He coaches aspiring entrepreneurs in Biotech and MedTech through the Advanced Masters Programme at the Solvay School of Economics and Management in Brussels, demonstrating his commitment not only to healthcare innovation but also to nurturing future leaders in the industry.

With a Bachelor of Science in Electrical Engineering and a Master's in Biomedical Engineering from the University of Montreal, along with an MBA from INSEAD, Lussier’s educational background complements his extensive professional experiences.

About Caristo Diagnostics

Founded in 2018 as a spin-off from the University of Oxford, Caristo Diagnostics aims to revolutionize cardiac and vascular disease diagnostics and risk prediction through advanced AI-assisted imaging platforms. Having earned recognition as one of the best digital health companies globally and highlighted by Newsweek and Nature, Caristo is poised to make significant strides in healthcare technology. The company continues to focus on innovative solutions to help prevent heart attacks, strokes, and other cardiovascular diseases.

With leaders like Michel Lussier on board, Caristo's future looks promising as it works toward making healthcare more accessible and effective for patients around the world.